Dr. Kyle M. Devins, MD
Pathology (Anatomic Pathology & Clinical Pathology Physician)
- Medicare participating
At a glance
- Medical school
- State University of Ny Upstate Medical University (2016)
- Years since graduation
- 10
- In the NPI registry since
- 2016
- Medicare patients seen, 2024
- 539
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2016Medical school: State University of Ny Upstate Medical University
- 2016Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Anatomic Pathology & Clinical Pathology Physician primary
MA license 282574 - Student in an Organized Health Care Education/Training Program
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Brigham and Women's Hospital Boston, MA
- Massachusetts General Hospital Boston, MA
- Massachusetts Eye and Ear Infirmary - Boston, MA
Medical groups
- Massachusetts General Physicians Organization Inc (3,558 clinicians)
- Brigham and Womens Physicians Organization Inc (2,994 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 539
- Services billed
- 1,652
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Pathology examination of tissue using a microscope, intermediate complexity | 455 | 304 |
| Special stained specimen slides to examine tissue, each additional procedure | 339 | 75 |
| Pathology examination of tissue using a microscope, moderately high complexity | 210 | 85 |
| Special stained specimen slides to examine tissue, initial procedure | 145 | 107 |
| Microscopic genetic analysis of tumor, manual | 106 | 56 |
| Pathology examination of specimen during surgery, first tissue block | 81 | 44 |
| Pathology examination of tissue using a microscope, high complexity | 57 | 46 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 57 | 56 |
| Surgical pathology, gross and microscopic examinations, for prostate needle biopsy, any method | 30 | 30 |
| Pathology examination of specimen during surgery, each additional tissue block | 19 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Payments from drug and device companies
In 2025, 2 companies reported 5 payments worth $11,513 in total to this clinician.
| Daiichi Sankyo Inc. | $8,213 |
|---|---|
| Verastem, Inc. | $3,300 |
| Consulting Fee | $11,513 |
|---|
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Daiichi Sankyo Inc. Mar 5, 2025 | Consulting Fee Enhertu · ONCOLOGY | $3,103 |
| Daiichi Sankyo Inc. Apr 9, 2025 | Consulting Fee Enhertu · ONCOLOGY | $2,920 |
| Daiichi Sankyo Inc. Mar 5, 2025 | Consulting Fee Enhertu · ONCOLOGY | $2,190 |
| Verastem, Inc. Dec 3, 2025 | Consulting Fee AVMAPKI FAKZYNJA CO-PACK · KRAS Mutated Recurrent Low-grade Serous Ovarian Cancer (LGSOC) | $1,650 |
| Verastem, Inc. Dec 11, 2025 | Consulting Fee AVMAPKI FAKZYNJA CO-PACK · KRAS Mutated Recurrent Low-grade Serous Ovarian Cancer (LGSOC) | $1,650 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.